Daniel Soffer
YOU?
Author Swipe
View article: A qualitative study to explore the patient experience of hypertriglyceridemia-related acute pancreatitis
A qualitative study to explore the patient experience of hypertriglyceridemia-related acute pancreatitis Open
HTG-AP has a substantial symptomatic and HRQoL burden during episodes, which can persist postrecovery. Treatments that reduce the incidence of HTG-AP have potential to improve HRQoL.
View article: Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America Open
Given its simplicity and high specificity for distinguishing patients with FCS from MCS, the NAFCS Score could be used in lieu of - or while awaiting - genetic testing to optimize treatment.
View article: New approaches to triglyceride reduction: Is there any hope left?
New approaches to triglyceride reduction: Is there any hope left? Open
Triglycerides play a crucial role in the efficient storage of energy in the body. Mild and moderate hypertriglyceridemia (HTG) is a heterogeneous disorder with significant association with atherosclerotic cardiovascular disease (ASCVD), in…
View article: FRI100 Lipoprotein X In Graft Vs. Host Disease Affecting Liver
FRI100 Lipoprotein X In Graft Vs. Host Disease Affecting Liver Open
Disclosure: D. Vedamurthy: None. C. Vitali: None. M. Cuchel: None. D. Soffer: None. D. Rader: None. Introduction: Lipoprotein-X (LpX) is an abnormal lipoprotein rich in phospholipid and unesterified cholesterol (UC) found in patients with …
View article: FRI090 Patterns Of Triglyceride Testing And Results Over Time Among Patients With Diabetes And Severe Hypertriglyceridemia In US Clinical Practice
FRI090 Patterns Of Triglyceride Testing And Results Over Time Among Patients With Diabetes And Severe Hypertriglyceridemia In US Clinical Practice Open
Disclosure: E. Kutrieb: Consulting Fee; Self; Ionis Pharmaceuticals Inc. S.J. Baum: Advisory Board Member; Self; Altimmune, Amgen Inc, Axcella, Boehringer Ingelheim, Eli Lilly & Company, Esperion, Madrigal Pharmaceuticals, Novartis Pharmac…
View article: FRI086 Statin Use After Lobar Intracerebral Hemorrhage- Is It Safe?
FRI086 Statin Use After Lobar Intracerebral Hemorrhage- Is It Safe? Open
Disclosure: D. Vedamurthy: None. M. Ambrosino: None. K. Suri: None. D. Soffer: None. D. Jacoby: None. Background: Observational studies and randomized clinical trials have yielded conflicting data on the role of statins in causing intracer…
View article: Feasibility of Lipid Screening During First Trimester of Pregnancy to Identify Women at Risk of Severe Dyslipidemia
Feasibility of Lipid Screening During First Trimester of Pregnancy to Identify Women at Risk of Severe Dyslipidemia Open
Background Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease, especially when disease presents at a young age. Despite national screening guidelines to perform a lipid profile test in children and young ad…
View article: Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia
Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia Open
Hypertriglyceridemia (HTG) is a prevalent medical condition in patients with cardiometabolic risk factors and is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), if left undiagnosed and undertreated. Cur…
View article: Estimated Atherosclerotic Cardiovascular Disease Risk Score: An Automated Decision Aid for Statin Therapy
Estimated Atherosclerotic Cardiovascular Disease Risk Score: An Automated Decision Aid for Statin Therapy Open
Background Estimation of atherosclerotic cardiovascular disease (ASCVD) risk is a key step in cardiovascular disease (CVD) prevention, but it requires entering additional risk factor information into a computer. We developed a simplified A…
View article: A new phenotypic classification system for dyslipidemias based on the standard lipid panel
A new phenotypic classification system for dyslipidemias based on the standard lipid panel Open
Background Dyslipoproteinemias can be classified by their distinct lipoprotein patterns, which helps determine atherosclerotic cardiovascular disease (ASCVD) risk and directs lipid management but this has required advanced laboratory testi…
View article: A New Phenotypic Classification System for Dyslipidemias Based on the Standard Lipid Panel
A New Phenotypic Classification System for Dyslipidemias Based on the Standard Lipid Panel Open
BACKGROUND Dyslipoproteinemias can be classified by their distinct lipoprotein patterns, which helps determine atherosclerotic cardiovascular disease (ASCVD) risk and directs lipid management but this has required advanced laboratory testi…
View article: Racial/Ethnic Disparities in Screening for and Awareness of High Cholesterol Among Pregnant Women Receiving Prenatal Care
Racial/Ethnic Disparities in Screening for and Awareness of High Cholesterol Among Pregnant Women Receiving Prenatal Care Open
Background Atherosclerotic cardiovascular disease remains a leading cause of morbidity and mortality among women, with younger women being disproportionately affected by traditional cardiovascular risk factors such as dyslipidemia. Despite…
View article: Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia Open
By adopting the 9 updated public policy recommendations created for this document, covering awareness; advocacy; screening, testing, and diagnosis; treatment; family-based care; registries; research; and cost and value, individual countrie…
View article: Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)
Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia) Open
HLP3 may be more prevalent than historically and clinically appreciated. The apoB method increases HLP3 identification via inclusion of milder phenotypes. Further work should evaluate the clinical implications of HLP3 diagnosis at various …
View article: Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia
Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia Open
Familial hypercholesterolemia (FH) is an autosomal co-dominant disorder marked by extremely high low-density lipoprotein (LDL) cholesterol levels and concomitant premature vascular disease. FH is caused by mutations that most commonly affe…